

13<sup>th</sup> August, 2021

**BSE Limited** 

Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001

**Scrip Code: 532300** 

**National Stock Exchange of India Limited** 

Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

**NSE Symbol – WOCKPHARMA** 

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

This is to inform you that Wockhardt Limited (the "Company") has entered into an agreement dated 12th August 2021 with Enso Healthcare DMCC ("Enso"), a company incorporated in Dubai, UAE and Human Vaccine LLC ("HV"), a wholly owned subsidiary of the "Management Company of Russian Direct Investment Fund", the sovereign wealth fund of the Russian Federation ("RDIF"), for the manufacture and supply of the Sputnik V / Sputnik Light vaccine against Covid-19. The agreement between the Company, HV, Enso was reached under the aegis of Enso, RDIF's coordination partner for sourcing Sputnik vaccine in India.

Subject to requisite approvals and other conditions, upon successful technology transfer from HV to the Company, the Company will manufacture and supply to Enso upto 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine against Covid-19.

Enclosed as **Annexure A** is the information required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Kindly take this information on record.

Thanking You,

For Wockhardt Limited

Debashis Dey Company Secretary





## **ANNEXURE A**

Disclosure of Information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, for receiving of orders / contracts not in the ordinary course of business by the listed entity

S. No.	Par	ticulars
1.	Name and brief particulars of the entity awarding the contract/ order	<ol> <li>Enso Healthcare DMCC ("Enso"), a company incorporated in Dubai, UAE.</li> <li>Human Vaccine LLC ("HV"), a wholly owned subsidiary of the Management Company of RDIF, the sovereign wealth fund of the Russian Federation.</li> </ol>
2.	Significant terms and conditions of the contract/ order	Contract manufacture of Sputnik V and Sputnik Light vaccine against Covid-19.
3.	Whether the contract/ order has been awarded by a domestic or an international entity	The contract/ order has been awarded by Enso, an international entity.
4.	Nature of contract/ order	Manufacturing Agreement
5.	Whether the contract/ order is domestic or international	The Manufacturing Agreement is an international contract.
6.	Time period by which the contract(s)/ order is to be executed	The term of the Manufacturing Agreement is upto June 2023 for the contract manufacturing of upto 620 million doses of Sputnik V and Sputnik Light, being initially upto June 30, 2022 which may be further extended upto June 30, 2023 subject to the terms of the contract.
7.	Size of the order	Upto 570-620 million injection doses of the Sputnik V vaccine / Sputnik Light vaccine, as below:  (i) 70-120 million injection doses upto June 30, 2022; and  (ii) Subject to certain conditions, a further 500 million injection doses between July 2022 – June, 2023





S. No.	Particulars	
8.	Whether the promoter/ promoter group / group companies have any interest in the entity that has awarded the contract(s)?	' '
	If yes, nature of interest and details thereof.	
9.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at an "arms' length"?	No, the transactions under these agreements would not be a related party transaction.

